Burkholderia pseudomallei and melioidosis.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
accepted:
04
09
2023
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
aheadofprint
Résumé
Burkholderia pseudomallei, the causative agent of melioidosis, is found in soil and water of tropical and subtropical regions globally. Modelled estimates of the global burden predict that melioidosis remains vastly under-reported, and a call has been made for it to be recognized as a neglected tropical disease by the World Health Organization. Severe weather events and environmental disturbance are associated with increased case numbers, and it is anticipated that, in some regions, cases will increase in association with climate change. Genomic epidemiological investigations have confirmed B. pseudomallei endemicity in newly recognized regions, including the southern United States. Melioidosis follows environmental exposure to B. pseudomallei and is associated with comorbidities that affect the immune response, such as diabetes, and with socioeconomic disadvantage. Several vaccine candidates are ready for phase I clinical trials. In this Review, we explore the global burden, epidemiology and pathophysiology of B. pseudomallei as well as current diagnostics, treatment recommendations and preventive measures, highlighting research needs and priorities.
Identifiants
pubmed: 37794173
doi: 10.1038/s41579-023-00972-5
pii: 10.1038/s41579-023-00972-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. Crown.
Références
Wiersinga, W. J. et al. Melioidosis. Nat. Rev. Dis. Primers 4, 17107 (2018).
pubmed: 29388572
pmcid: 6456913
doi: 10.1038/nrdp.2017.107
Cheng, A. C., Jacups, S. P., Gal, D., Mayo, M. & Currie, B. J. Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int. J. Epidemiol. 35, 323–329 (2006).
pubmed: 16326823
doi: 10.1093/ije/dyi271
Limmathurotsakul, D. et al. Melioidosis caused by Burkholderia pseudomallei in drinking water, Thailand, 2012. Emerg. Infect. Dis. 20, 265–268 (2014).
pubmed: 24447771
pmcid: 3901481
doi: 10.3201/eid2002.121891
Gee, J. E. et al. Multistate outbreak of melioidosis associated with imported aromatherapy spray. N. Engl. J. Med. 386, 861–868 (2022). This study demonstrates the power of combining bacterial genomics with field epidemiology to track a melioidosis outbreak from source to patients.
pubmed: 35235727
pmcid: 10243137
doi: 10.1056/NEJMoa2116130
Sarovich, D. S. et al. Whole-genome sequencing to investigate a non-clonal melioidosis cluster on a remote Australian island. Microb. Genom. 3, e000117 (2017).
pubmed: 29026657
pmcid: 5610713
McRobb, E. et al. Tracing melioidosis back to the source: using whole-genome sequencing to investigate an outbreak originating from a contaminated domestic water supply. J. Clin. Microbiol. 53, 1144–1148 (2015).
pubmed: 25631791
pmcid: 4365233
doi: 10.1128/JCM.03453-14
Birnie, E., Biemond, J. J. & Wiersinga, W. J. Drivers of melioidosis endemicity: epidemiological transition, zoonosis, and climate change. Curr. Opin. Infect. Dis. 35, 196–204 (2022).
pubmed: 35665713
pmcid: 10128909
doi: 10.1097/QCO.0000000000000827
Sprague, L. D. & Neubauer, H. Melioidosis in animals: a review on epizootiology, diagnosis and clinical presentation. J. Vet. Med. B Infect. Dis. Vet. Public Health 51, 305–320 (2004).
pubmed: 15525357
doi: 10.1111/j.1439-0450.2004.00797.x
Currie, B. J. et al. The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. Lancet Infect. Dis. 21, 1737–1746 (2021). A comprehensive analysis of the epidemiology and clinical features of melioidosis in the Northern Territory of Australia over three decades.
pubmed: 34303419
doi: 10.1016/S1473-3099(21)00022-0
Chantratita, N. et al. Characteristics and one year outcomes of melioidosis patients in northeastern Thailand: a prospective, multicenter cohort study. Lancet Reg. Health Southeast Asia 9, 100118 (2023). A prospective cohort study describing the epidemiology, clinical features and outcomes of 2,574 melioidosis cases in northeastern Thailand.
pubmed: 36570973
doi: 10.1016/j.lansea.2022.100118
Limmathurotsakul, D. et al. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 82, 1113–1117 (2010).
pubmed: 20519609
pmcid: 2877420
doi: 10.4269/ajtmh.2010.10-0038
Limmathurotsakul, D. et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol. 1, 15008 (2016). A global map of melioidosis locations and numbers, both known and predicted from modelling, set as a benchmark for future validation.
pubmed: 27571754
pmcid: 4746747
doi: 10.1038/nmicrobiol.2015.8
Currie, B. J. Melioidosis and Burkholderia pseudomallei: progress in epidemiology, diagnosis, treatment and vaccination. Curr. Opin. Infect. Dis. 35, 517–523 (2022).
pubmed: 35942848
doi: 10.1097/QCO.0000000000000869
Centers for Disease Control and Prevention. Bacteria that Causes Rare Disease Melioidosis Discovered in U.S. Environmental Samples. CDC https://www.cdc.gov/media/releases/2022/p0727-Melioidosis.html (2022).
Gassiep, I. et al. Expanding the geographic boundaries of melioidosis in Queensland, Australia. Am. J. Trop. Med. Hyg. 108, 1215–1219 (2023).
pubmed: 37160276
doi: 10.4269/ajtmh.23-0002
Savelkoel, J., Dance, D. A. B., Currie, B. J., Limmathurotsakul, D. & Wiersinga, W. J. A call to action: time to recognise melioidosis as a neglected tropical disease. Lancet Infect. Dis. 22, e176–e182 (2022).
pubmed: 34953519
doi: 10.1016/S1473-3099(21)00394-7
Suputtamongkol, Y. et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int. J. Epidemiol. 23, 1082–1090 (1994).
pubmed: 7860160
doi: 10.1093/ije/23.5.1082
Hodgetts, K. et al. Melioidosis in the remote Katherine region of northern Australia. PLoS Negl. Trop. Dis. 16, e0010486 (2022).
pubmed: 35696415
pmcid: 9232150
doi: 10.1371/journal.pntd.0010486
Hanson, J., Smith, S., Stewart, J., Horne, P. & Ramsamy, N. Melioidosis — a disease of socioeconomic disadvantage. PLoS Negl. Trop. Dis. 15, e0009544 (2021).
pubmed: 34153059
pmcid: 8248627
doi: 10.1371/journal.pntd.0009544
McLeod, C. et al. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern Territory of Australia and review of the literature. Clin. Infect. Dis. 60, 21–26 (2015).
pubmed: 25228703
doi: 10.1093/cid/ciu733
Stoesser, N. et al. Pediatric suppurative parotitis in Cambodia between 2007 and 2011. Pediatr. Infect. Dis. J. 31, 865–868 (2012).
pubmed: 22531239
pmcid: 3400948
doi: 10.1097/INF.0b013e318258873b
Currie, B. J. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin. Respir. Crit. Care Med. 36, 111–125 (2015).
pubmed: 25643275
doi: 10.1055/s-0034-1398389
Limmathurotsakul, D. et al. Activities of daily living associated with acquisition of melioidosis in northeast Thailand: a matched case-control study. PLoS Negl. Trop. Dis. 7, e2072 (2013).
pubmed: 23437412
pmcid: 3578767
doi: 10.1371/journal.pntd.0002072
Wuthiekanun, V. et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am. J. Trop. Med. Hyg. 74, 1074–1075 (2006).
pubmed: 16760522
doi: 10.4269/ajtmh.2006.74.1074
James, G. L. et al. Surprisingly low seroprevalence of Burkholderia pseudomallei in exposed healthy adults in the Darwin region of tropical Australia where melioidosis is highly endemic. Clin. Vaccin. Immunol. 20, 759–760 (2013).
doi: 10.1128/CVI.00021-13
Time. Diseases: Viet Nam’s Time Bomb. Time https://content.time.com/time/subscriber/article/0,33009,840848,00.html (1967).
Kingston, C. W. Chronic or latent melioidosis. Med. J. Aust. 2, 618–621 (1971).
pubmed: 5114173
doi: 10.5694/j.1326-5377.1971.tb92445.x
Mays, E. E. & Ricketts, E. A. Melioidosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest 68, 261–263 (1975).
pubmed: 1149556
doi: 10.1378/chest.68.2.261
Chodimella, U., Hoppes, W. L., Whalen, S., Ognibene, A. J. & Rutecki, G. W. Septicemia and suppuration in a Vietnam veteran. Hosp. Pract. 32, 219–221 (1997).
doi: 10.1080/21548331.1997.11443493
Suputtamongkol, Y. et al. Risk factors for melioidosis and bacteremic melioidosis. Clin. Infect. Dis. 29, 408–413 (1999).
pubmed: 10476750
doi: 10.1086/520223
Geake, J. B. et al. An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulm. Med. 15, 116 (2015).
pubmed: 26453341
pmcid: 4600338
doi: 10.1186/s12890-015-0109-9
Birnie, E. et al. Global burden of melioidosis in 2015: a systematic review and data synthesis. Lancet Infect. Dis. 19, 892–902 (2019).
pubmed: 31285144
pmcid: 6867904
doi: 10.1016/S1473-3099(19)30157-4
Trinh, T. T. et al. A simple laboratory algorithm for diagnosis of melioidosis in resource-constrained areas: a study from north-central Vietnam. Clin. Microbiol. Infect. 24, 84.e1–84.e4 (2018). This study demonstrated the effectiveness of disc diffusion antimicrobial susceptibility testing of amoxicillin–clavulanate (susceptible), gentamicin (resistant) and colistin (resistant) for the presumptive identification of B. pseudomallei.
pubmed: 28780059
doi: 10.1016/j.cmi.2017.07.029
Dance, D. A. B. et al. Evaluation of consensus method for the culture of Burkholderia pseudomallei in soil samples from Laos. Wellcome Open Res. 3, 132 (2018).
pubmed: 30569022
pmcid: 6283377
doi: 10.12688/wellcomeopenres.14851.2
Shaw, T. et al. Environmental factors associated with soil prevalence of the melioidosis pathogen Burkholderia pseudomallei: a longitudinal seasonal study from South West India. Front. Microbiol. 13, 902996 (2022).
pubmed: 35847064
pmcid: 9283100
doi: 10.3389/fmicb.2022.902996
Oduro, G. et al. On the environmental presence of Burkholderia pseudomallei in South-Central Ghana. Appl. Env. Microbiol. 88, e0060022 (2022).
doi: 10.1128/aem.00600-22
Cossaboom, C. M. et al. Melioidosis in a resident of Texas with no recent travel history, United States. Emerg. Infect. Dis. 26, 1295–1299 (2020).
pubmed: 32442394
pmcid: 7258475
doi: 10.3201/eid2606.190975
Palasatien, S., Lertsirivorakul, R., Royros, P., Wongratanacheewin, S. & Sermswan, R. W. Soil physicochemical properties related to the presence of Burkholderia pseudomallei. Trans. R. Soc. Trop. Med. Hyg. 102 (Suppl. 1), 5–9 (2008).
doi: 10.1016/S0035-9203(08)70003-8
Hantrakun, V. et al. Soil nutrient depletion is associated with the presence of Burkholderia pseudomallei. Appl. Env. Microbiol. 82, 7086–7092 (2016).
doi: 10.1128/AEM.02538-16
Inglis, T. J. & Sagripanti, J. L. Environmental factors that affect the survival and persistence of Burkholderia pseudomallei. Appl. Env. Microbiol. 72, 6865–6875 (2006).
doi: 10.1128/AEM.01036-06
Yip, T. W. et al. Endemic melioidosis in residents of desert region after atypically intense rainfall in central Australia, 2011. Emerg. Infect. Dis. 21, 1038–1040 (2015).
pubmed: 25988301
pmcid: 4451904
doi: 10.3201/eid2106.141908
Chapple, S. N. J. et al. Whole-genome sequencing of a quarter-century melioidosis outbreak in temperate Australia uncovers a region of low-prevalence endemicity. Microb. Genom. 2, e000067 (2016).
pubmed: 28348862
pmcid: 5343139
Kaestli, M. et al. Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia. PLoS Negl. Trop. Dis. 3, e364 (2009).
pubmed: 19156200
pmcid: 2617783
doi: 10.1371/journal.pntd.0000364
Pongmala, K. et al. Distribution of Burkholderia pseudomallei within a 300-cm deep soil profile: implications for environmental sampling. Sci. Rep. 12, 8674 (2022). A detailed investigation of the complex associations between the physicochemical properties of soil and B. pseudomallei to a depth of 3 m.
pubmed: 35606475
pmcid: 9126866
doi: 10.1038/s41598-022-12795-0
Baker, A. L., Ezzahir, J., Gardiner, C., Shipton, W. & Warner, J. M. Environmental attributes influencing the distribution of Burkholderia pseudomallei in northern Australia. PLoS ONE 10, e0138953 (2015).
pubmed: 26398904
pmcid: 4580599
doi: 10.1371/journal.pone.0138953
Kaestli, M. et al. Opportunistic pathogens and large microbial diversity detected in source-to-distribution drinking water of three remote communities in Northern Australia. PLoS Negl. Trop. Dis. 13, e0007672 (2019).
pubmed: 31487283
pmcid: 6728021
doi: 10.1371/journal.pntd.0007672
Limmathurotsakul, D. et al. Systematic review and consensus guidelines for environmental sampling of Burkholderia pseudomallei. PLoS Negl. Trop. Dis. 7, e2105 (2013).
pubmed: 23556010
pmcid: 3605150
doi: 10.1371/journal.pntd.0002105
Kaestli, M. et al. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. Env. Microbiol. 14, 2058–2070 (2012).
doi: 10.1111/j.1462-2920.2011.02671.x
Hoger, A. C. et al. The melioidosis agent Burkholderia pseudomallei and related opportunistic pathogens detected in faecal matter of wildlife and livestock in northern Australia. Epidemiol. Infect. 144, 1924–1932 (2016).
pubmed: 26935879
doi: 10.1017/S0950268816000285
Wuthiekanun, V., Smith, M. D., Dance, D. A. & White, N. J. Isolation of Pseudomonas pseudomallei from soil in north-eastern Thailand. Trans. R. Soc. Trop. Med. Hyg. 89, 41–43 (1995).
pubmed: 7538233
doi: 10.1016/0035-9203(95)90651-7
Kaestli, M. et al. What drives the occurrence of the melioidosis bacterium Burkholderia pseudomallei in domestic gardens? PLoS Negl. Trop. Dis. 9, e0003635 (2015).
pubmed: 25803046
pmcid: 4372393
doi: 10.1371/journal.pntd.0003635
Rachlin, A. et al. Whole-genome sequencing of Burkholderia pseudomallei from an urban melioidosis hot spot reveals a fine-scale population structure and localised spatial clustering in the environment. Sci. Rep. 10, 5443 (2020).
pubmed: 32214186
pmcid: 7096523
doi: 10.1038/s41598-020-62300-8
Smith, S. et al. Increased incidence of melioidosis in far North Queensland, Queensland, Australia, 1998-2019. Emerg. Infect. Dis. 27, 3119–3123 (2021).
pubmed: 34808088
pmcid: 8632158
doi: 10.3201/eid2712.211302
Ribolzi, O. et al. Land use and soil type determine the presence of the pathogen Burkholderia pseudomallei in tropical rivers. Env. Sci. Pollut. Res. Int. 23, 7828–7839 (2016).
doi: 10.1007/s11356-015-5943-z
Zimmermann, R. E. et al. Rivers as carriers and potential sentinels for Burkholderia pseudomallei in Laos. Sci. Rep. 8, 8674 (2018).
pubmed: 29875361
pmcid: 5989208
doi: 10.1038/s41598-018-26684-y
Baker, A. et al. Groundwater seeps facilitate exposure to Burkholderia pseudomallei. Appl. Env. Microbiol. 77, 7243–7246 (2011).
doi: 10.1128/AEM.05048-11
Mayo, M. et al. Burkholderia pseudomallei in unchlorinated domestic bore water, tropical Northern Australia. Emerg. Infect. Dis. 17, 1283–1285 (2011).
pubmed: 21762588
pmcid: 3381386
doi: 10.3201/eid1707.100614
Howard, K. & Inglis, T. J. The effect of free chlorine on Burkholderia pseudomallei in potable water. Water Res. 37, 4425–4432 (2003).
pubmed: 14511713
doi: 10.1016/S0043-1354(03)00440-8
Chen, P. S. et al. Airborne transmission of melioidosis to humans from environmental aerosols contaminated with B. pseudomallei. PLoS Negl. Trop. Dis. 9, e0003834 (2015).
pubmed: 26061639
pmcid: 4462588
doi: 10.1371/journal.pntd.0003834
Sagripanti, J. L., Levy, A., Robertson, J., Merritt, A. & Inglis, T. J. Inactivation of virulent Burkholderia pseudomallei by sunlight. Photochem. Photobiol. 85, 978–986 (2009).
pubmed: 19192198
doi: 10.1111/j.1751-1097.2008.00518.x
Thomas, A. D., Forbes-Faulkner, J. & Parker, M. Isolation of Pseudomonas pseudomallei from clay layers at defined depths. Am. J. Epidemiol. 110, 515–521 (1979).
pubmed: 507042
doi: 10.1093/oxfordjournals.aje.a112832
Kaestli, M. et al. The association of melioidosis with climatic factors in Darwin, Australia: a 23-year time-series analysis. J. Infect. 72, 687–697 (2016).
pubmed: 26945846
doi: 10.1016/j.jinf.2016.02.015
Bulterys, P. L. et al. Climatic drivers of melioidosis in Laos and Cambodia: a 16-year case series analysis. Lancet Planet. Health 2, e334–e343 (2018).
pubmed: 30082048
pmcid: 6076299
doi: 10.1016/S2542-5196(18)30172-4
Merritt, A. J. & Inglis, T. J. J. The role of climate in the epidemiology of melioidosis. Curr. Trop. Med. Rep. 4, 185–191 (2017).
pubmed: 29188170
pmcid: 5684260
doi: 10.1007/s40475-017-0124-4
Holden, M. T. et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl Acad. Sci. USA 101, 14240–14245 (2004).
pubmed: 15377794
pmcid: 521101
doi: 10.1073/pnas.0403302101
Price, E. P., Currie, B. J. & Sarovich, D. S. Genomic insights into the melioidosis pathogen, Burkholderia pseudomallei. Curr. Trop. Med. Rep. 4, 95–102 (2017).
doi: 10.1007/s40475-017-0111-9
Spring-Pearson, S. M. et al. Pangenome analysis of Burkholderia pseudomallei: genome evolution preserves gene order despite high recombination rates. PLoS ONE 10, e0140274 (2015).
pubmed: 26484663
pmcid: 4613141
doi: 10.1371/journal.pone.0140274
Tuanyok, A. et al. Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics 9, 566 (2008).
pubmed: 19038032
pmcid: 2612704
doi: 10.1186/1471-2164-9-566
Tumapa, S. et al. Burkholderia pseudomallei genome plasticity associated with genomic island variation. BMC Genomics 9, 190 (2008).
pubmed: 18439288
pmcid: 2386483
doi: 10.1186/1471-2164-9-190
Chewapreecha, C. et al. Co-evolutionary signals identify Burkholderia pseudomallei survival strategies in a hostile environment. Mol. Biol. Evol. 39, msab306 (2022).
pubmed: 34662416
doi: 10.1093/molbev/msab306
Ooi, W. F. et al. The condition-dependent transcriptional landscape of Burkholderia pseudomallei. PLoS Genet. 9, e1003795 (2013).
pubmed: 24068961
pmcid: 3772027
doi: 10.1371/journal.pgen.1003795
Sarovich, D. S. et al. Variable virulence factors in Burkholderia pseudomallei (melioidosis) associated with human disease. PLoS ONE 9, e91682 (2014).
pubmed: 24618705
pmcid: 3950250
doi: 10.1371/journal.pone.0091682
Gora, H. et al. Melioidosis of the central nervous system; impact of the bimA
doi: 10.1093/cid/ciac111
pubmed: 35137005
Chewapreecha, C. et al. Genetic variation associated with infection and the environment in the accidental pathogen Burkholderia pseudomallei. Commun. Biol. 2, 428 (2019).
pubmed: 31799430
pmcid: 6874650
doi: 10.1038/s42003-019-0678-x
Price, E. P. et al. Unprecedented melioidosis cases in Northern Australia caused by an Asian Burkholderia pseudomallei strain identified by using large-scale comparative genomics. Appl. Env. Microbiol. 82, 954–963 (2016).
doi: 10.1128/AEM.03013-15
Pearson, T. et al. Phylogeographic reconstruction of a bacterial species with high levels of lateral gene transfer. BMC Biol. 7, 78 (2009).
pubmed: 19922616
pmcid: 2784454
doi: 10.1186/1741-7007-7-78
Chewapreecha, C. et al. Global and regional dissemination and evolution of Burkholderia pseudomallei. Nat. Microbiol. 2, 16263 (2017). A multinational collaboration using bacterial genomics to map and estimate predicted timing for the global spread of B. pseudomallei.
pubmed: 28112723
pmcid: 5300093
doi: 10.1038/nmicrobiol.2016.263
Gee, J. E. et al. Phylogeography of Burkholderia pseudomallei isolates, Western hemisphere. Emerg. Infect. Dis. 23, 1133–1138 (2017).
pubmed: 28628442
pmcid: 5512505
doi: 10.3201/eid2307.161978
Ngauy, V., Lemeshev, Y., Sadkowski, L. & Crawford, G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol. 43, 970–972 (2005).
pubmed: 15695721
pmcid: 548040
doi: 10.1128/JCM.43.2.970-972.2005
Meumann, E. M. et al. Emergence of Burkholderia pseudomallei sequence type 562, northern Australia. Emerg. Infect. Dis. 27, 1057–1067 (2021).
pubmed: 33754984
pmcid: 8007296
doi: 10.3201/eid2704.202716
Webb, J. R. et al. Genomic epidemiology links Burkholderia pseudomallei from individual human cases to B. pseudomallei from targeted environmental sampling in northern Australia. J. Clin. Microbiol. 60, e0164821 (2022).
pubmed: 35080450
doi: 10.1128/jcm.01648-21
Lichtenegger, S. et al. Development and validation of a Burkholderia pseudomallei core genome multilocus sequence typing scheme to facilitate molecular surveillance. J. Clin. Microbiol. 59, e0009321 (2021).
pubmed: 33980649
doi: 10.1128/JCM.00093-21
Ku, J. W. & Gan, Y. H. Modulation of bacterial virulence and fitness by host glutathione. Curr. Opin. Microbiol. 47, 8–13 (2019).
pubmed: 30396015
doi: 10.1016/j.mib.2018.10.004
Stevens, M. P. et al. Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei. Mol. Microbiol. 56, 40–53 (2005).
pubmed: 15773977
doi: 10.1111/j.1365-2958.2004.04528.x
Mobbs, G. W. et al. Molecular basis of specificity and deamidation of eIF4A by Burkholderia lethal factor 1. Commun. Biol. 5, 272 (2022).
pubmed: 35347220
pmcid: 8960835
doi: 10.1038/s42003-022-03186-2
Birnie, E. et al. Role of Toll-like receptor 5 (TLR5) in experimental melioidosis. Infect. Immun. 87, e00409-18 (2019).
pubmed: 31109950
pmcid: 6652761
doi: 10.1128/IAI.00409-18
Chomkatekaew, C., Boonklang, P., Sangphukieo, A. & Chewapreecha, C. An evolutionary arms race between Burkholderia pseudomallei and host immune system: what do we know? Front. Microbiol. 11, 612568 (2020).
pubmed: 33552023
doi: 10.3389/fmicb.2020.612568
Trottmann, F. et al. Pathogenic bacteria remodel central metabolic enzyme to build a cyclopropanol warhead. Nat. Chem. 14, 884–890 (2022). This study identifies malleicyprols as a novel B. pseudomallei virulence factor.
pubmed: 35906404
pmcid: 9359912
doi: 10.1038/s41557-022-01005-z
Pearson, T. et al. Pathogen to commensal? Longitudinal within-host population dynamics, evolution, and adaptation during a chronic >16-year Burkholderia pseudomallei infection. PLoS Pathog. 16, e1008298 (2020). Interesting case study demonstrating the evolutionary progression of a highly virulent B. pseudomallei strain towards commensalism within a single human host.
pubmed: 32134991
pmcid: 7077878
doi: 10.1371/journal.ppat.1008298
Viberg, L. T. et al. Within-host evolution of Burkholderia pseudomallei during chronic infection of seven Australasian cystic fibrosis patients. mBio 8, e00356-17(2017).
pubmed: 28400528
pmcid: 5388805
doi: 10.1128/mBio.00356-17
Jones, A. L., Beveridge, T. J. & Woods, D. E. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 64, 782–790 (1996).
pubmed: 8641782
pmcid: 173838
doi: 10.1128/iai.64.3.782-790.1996
Heacock-Kang, Y. et al. The Burkholderia pseudomallei intracellular ‘TRANSITome’. Nat. Commun. 12, 1907 (2021). Description of the B. pseudomallei ‘TRANSITome’, which reveals a dynamic gene-expression flux during transit in host cells identifying genes that are required for pathogenesis.
pubmed: 33772012
pmcid: 7998038
doi: 10.1038/s41467-021-22169-1
Wiersinga, W. J. et al. Toll-like receptor 2 impairs host defense in Gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Med. 4, e248 (2007).
pubmed: 17676990
pmcid: 1950213
doi: 10.1371/journal.pmed.0040248
West, T. E., Ernst, R. K., Jansson-Hutson, M. J. & Skerrett, S. J. Activation of toll-like receptors by Burkholderia pseudomallei. BMC Immunol. 9, 46 (2008).
pubmed: 18691413
pmcid: 2527550
doi: 10.1186/1471-2172-9-46
West, T. E. et al. Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis. Genes Immun. 13, 38–46 (2012).
pubmed: 21776015
doi: 10.1038/gene.2011.49
West, T. E. et al. Impaired TLR5 functionality is associated with survival in melioidosis. J. Immunol. 190, 3373–3379 (2013).
pubmed: 23447684
pmcid: 3607401
doi: 10.4049/jimmunol.1202974
Ceballos-Olvera, I., Sahoo, M., Miller, M. A., Del Barrio, L. & Re, F. Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1β is deleterious. PLoS Pathog. 7, e1002452 (2011).
pubmed: 22241982
pmcid: 3248555
doi: 10.1371/journal.ppat.1002452
Weehuizen, T. A. et al. Therapeutic administration of a monoclonal anti-Il-1β antibody protects against experimental melioidosis. Shock 46, 566–574 (2016).
pubmed: 27219859
pmcid: 5058638
doi: 10.1097/SHK.0000000000000625
West, T. E. et al. NLRC4 and TLR5 each contribute to host defense in respiratory melioidosis. PLoS Negl. Trop. Dis. 8, e3178 (2014).
pubmed: 25232720
pmcid: 4169243
doi: 10.1371/journal.pntd.0003178
Myers, N. D. et al. The role of NOD2 in murine and human melioidosis. J. Immunol. 192, 300–307 (2014).
pubmed: 24298015
doi: 10.4049/jimmunol.1301436
Bast, A. et al. Caspase-1-dependent and -independent cell death pathways in Burkholderia pseudomallei infection of macrophages. PLoS Pathog. 10, e1003986 (2014).
pubmed: 24626296
pmcid: 3953413
doi: 10.1371/journal.ppat.1003986
Easton, A., Haque, A., Chu, K., Lukaszewski, R. & Bancroft, G. J. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J. Infect. Dis. 195, 99–107 (2007).
pubmed: 17152013
doi: 10.1086/509810
Sanchez-Villamil, J. I., Tapia, D., Khakhum, N., Widen, S. G. & Torres, A. G. Dual RNA-seq reveals a type 6 secretion system-dependent blockage of TNF-α signaling and BicA as a Burkholderia pseudomallei virulence factor important during gastrointestinal infection. Gut Microbes 14, 2111950 (2022).
pubmed: 35984745
pmcid: 9397134
doi: 10.1080/19490976.2022.2111950
Kager, L. M. et al. Mice lacking the lectin-like domain of thrombomodulin are protected against melioidosis. Crit. Care Med. 42, e221–e230 (2014).
pubmed: 24399241
doi: 10.1097/CCM.0000000000000134
Whiteley, L. et al. Entry, intracellular survival, and multinucleated-giant-cell-forming activity of Burkholderia pseudomallei in human primary phagocytic and nonphagocytic cells. Infect. Immun. 85, e00468-17 (2017).
pubmed: 28760929
pmcid: 5607410
doi: 10.1128/IAI.00468-17
Wiersinga, W. J. et al. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit. Care Med. 37, 569–576 (2009).
pubmed: 19114913
doi: 10.1097/CCM.0b013e318194b1bf
Yimthin, T. et al. Blood transcriptomics to characterize key biological pathways and identify biomarkers for predicting mortality in melioidosis. Emerg. Microbes Infect. 10, 8–18 (2021).
pubmed: 33256556
pmcid: 7832033
doi: 10.1080/22221751.2020.1858176
Natesan, M. et al. Calprotectin as a biomarker for melioidosis disease progression and management. J. Clin. Microbiol. 55, 1205–1210 (2017).
pubmed: 28179407
pmcid: 5377848
doi: 10.1128/JCM.02284-16
de Jong, H. K. et al. Neutrophil extracellular traps in the host defense against sepsis induced by Burkholderia pseudomallei (melioidosis). Intensive Care Med. Exp. 2, 21 (2014).
pubmed: 26215706
pmcid: 4678137
doi: 10.1186/s40635-014-0021-2
Riyapa, D. et al. Neutrophil extracellular traps exhibit antibacterial activity against Burkholderia pseudomallei and are influenced by bacterial and host factors. Infect. Immun. 80, 3921–3929 (2012). Evidence of the importance of neutrophils and NETs in host defence against B. pseudomallei.
pubmed: 22927051
pmcid: 3486034
doi: 10.1128/IAI.00806-12
Syed, I. & Wooten, R. M. Interactions between pathogenic Burkholderia and the complement system: a review of potential immune evasion mechanisms. Front. Cell Infect. Microbiol. 11, 701362 (2021).
pubmed: 34660335
pmcid: 8515183
doi: 10.3389/fcimb.2021.701362
DeShazer, D., Brett, P. J. & Woods, D. E. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol. Microbiol. 30, 1081–1100 (1998).
pubmed: 9988483
doi: 10.1046/j.1365-2958.1998.01139.x
Wiersinga, W. J. et al. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J. Thromb. Haemost. 6, 32–39 (2008).
pubmed: 17944999
doi: 10.1111/j.1538-7836.2007.02796.x
Birnie, E. et al. Thrombocytopenia impairs host defense against Burkholderia pseudomallei (melioidosis). J. Infect. Dis. 219, 648–659 (2019). Translational study showing the protective effect of platelets in host defence against B. pseudomallei.
pubmed: 30312422
doi: 10.1093/infdis/jiy541
Ketheesan, N. et al. Demonstration of a cell-mediated immune response in melioidosis. J. Infect. Dis. 186, 286–289 (2002).
pubmed: 12134268
doi: 10.1086/341222
Jenjaroen, K. et al. T-cell responses are associated with survival in acute melioidosis patients. PLoS Negl. Trop. Dis. 9, e0004152 (2015). Demonstration that CD4
pubmed: 26495852
pmcid: 4619742
doi: 10.1371/journal.pntd.0004152
Kronsteiner, B. et al. Diabetes alters immune response patterns to acute melioidosis in humans. Eur. J. Immunol. 49, 1092–1106 (2019).
pubmed: 31032897
pmcid: 6618312
doi: 10.1002/eji.201848037
Reynolds, C. et al. T cell immunity to the alkyl hydroperoxide reductase of Burkholderia pseudomallei: a correlate of disease outcome in acute melioidosis. J. Immunol. 194, 4814–4824 (2015).
pubmed: 25862821
pmcid: 4416739
doi: 10.4049/jimmunol.1402862
Dunachie, S. J. et al. Infection with Burkholderia pseudomallei — immune correlates of survival in acute melioidosis. Sci. Rep. 7, 12143 (2017).
pubmed: 28939855
pmcid: 5610189
doi: 10.1038/s41598-017-12331-5
Sengyee, S. et al. Melioidosis patient survival correlates with strong IFN-γ secreting T cell responses against Hcp1 and TssM. Front. Immunol. 12, 698303 (2021).
pubmed: 34394091
pmcid: 8363298
doi: 10.3389/fimmu.2021.698303
Healey, G. D., Elvin, S. J., Morton, M. & Williamson, E. D. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect. Immun. 73, 5945–5951 (2005).
pubmed: 16113315
pmcid: 1231116
doi: 10.1128/IAI.73.9.5945-5951.2005
Haque, A. et al. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J. Infect. Dis. 193, 370–379 (2006).
pubmed: 16388484
doi: 10.1086/498983
Chaichana, P. et al. Role of Burkholderia pseudomallei-specific IgG2 in adults with acute melioidosis, Thailand. Emerg. Infect. Dis. 27, 463–470 (2021).
pubmed: 33496230
pmcid: 7853568
doi: 10.3201/eid2702.200213
Pumpuang, A. et al. Distinct classes and subclasses of antibodies to hemolysin co-regulated protein 1 and O-polysaccharide and correlation with clinical characteristics of melioidosis patients. Sci. Rep. 9, 13972 (2019).
pubmed: 31562344
pmcid: 6764960
doi: 10.1038/s41598-019-48828-4
Rongkard, P. et al. Human immune responses to melioidosis and cross-reactivity to low-virulence Burkholderia species, Thailand. Emerg. Infect. Dis. 26, 463–471 (2020).
pubmed: 32091359
pmcid: 7045851
doi: 10.3201/eid2603.190206
Peacock, S. J. et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg. Infect. Dis. 14, e2 (2008).
pubmed: 18598617
pmcid: 2600349
doi: 10.3201/eid1407.071501
Gassiep, I., Bauer, M. J., Harris, P. N. A., Chatfield, M. D. & Norton, R. Laboratory safety: handling Burkholderia pseudomallei isolates without a biosafety cabinet. J. Clin. Microbiol. 59, e0042421 (2021). This study demonstrates no evidence of laboratory-acquired B. pseudomallei infection despite handling of the organism without a biosafety cabinet.
pubmed: 33910967
doi: 10.1128/JCM.00424-21
Gassiep, I., Armstrong, M. & Norton, R. Human melioidosis.Clin. Microbiol. Rev. 33, e00006-19 (2020).
pubmed: 32161067
pmcid: 7067580
doi: 10.1128/CMR.00006-19
Anuntagool, N. et al. Monoclonal antibody-based rapid identification of Burkholderia pseudomallei in blood culture fluid from patients with community-acquired septicaemia. J. Med. Microbiol. 49, 1075–1078 (2000).
pubmed: 11129718
doi: 10.1099/0022-1317-49-12-1075
Duval, B. D. et al. Evaluation of a latex agglutination assay for the identification of Burkholderia pseudomallei and Burkholderia mallei. Am. J. Trop. Med. Hyg. 90, 1043–1046 (2014).
pubmed: 24710616
pmcid: 4047727
doi: 10.4269/ajtmh.14-0025
Hoffmaster, A. R. et al. Melioidosis diagnostic workshop, 2013. Emerg. Infect. Dis. 21, e141045 (2015).
pubmed: 25626057
pmcid: 4313648
Podin, Y. et al. Burkholderia pseudomallei isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides. Antimicrob. Agents Chemother. 58, 162–166 (2014).
pubmed: 24145517
pmcid: 3910780
doi: 10.1128/AAC.01842-13
Lowe, P., Haswell, H. & Lewis, K. Use of various common isolation media to evaluate the new VITEK 2 colorimetric GN Card for identification of Burkholderia pseudomallei. J. Clin. Microbiol. 44, 854–856 (2006).
pubmed: 16517866
pmcid: 1393156
doi: 10.1128/JCM.44.3.854-856.2006
Deepak, R. N., Crawley, B. & Phang, E. Burkholderia pseudomallei identification: a comparison between the API 20NE and VITEK 2 GN systems. Trans. R. Soc. Trop. Med. Hyg. 102 (Suppl. 1), 42–44 (2008).
doi: 10.1016/S0035-9203(08)70012-9
Gassiep, I., Armstrong, M. & Norton, R. E. Identification of Burkholderia pseudomallei by use of the Vitek mass spectrometer. J. Clin. Microbiol. 57, e00081-19 (2019).
pubmed: 30842230
pmcid: 6498004
doi: 10.1128/JCM.00081-19
Watthanaworawit, W. et al. A multi-country study using MALDI-TOF mass spectrometry for rapid identification of Burkholderia pseudomallei. BMC Microbiol. 21, 213 (2021).
pubmed: 34266382
pmcid: 8283998
doi: 10.1186/s12866-021-02276-1
Dingle, T. C., Butler-Wu, S. M. & Abbott, A. N. Accidental exposure to Burkholderia pseudomallei in the laboratory in the era of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 52, 3490–3491 (2014).
pubmed: 24920780
pmcid: 4313193
doi: 10.1128/JCM.01238-14
Karatuna, O. et al. Burkholderia pseudomallei multi-centre study to establish EUCAST MIC and zone diameter distributions and epidemiological cut-off values. Clin. Microbiol. Infect. 27, 736–741 (2021). This multinational study established MIC and zone diameter distributions to determine epidemiological cut-off values for antimicrobials used to treat melioidosis; these data have informed the development of EUCAST clinical breakpoints.
doi: 10.1016/j.cmi.2020.07.001
Dance, D. A. B. et al. Interpreting Burkholderia pseudomallei disc diffusion susceptibility test results by the EUCAST method. Clin. Microbiol. Infect. 27, 827–829 (2021).
pubmed: 33636339
doi: 10.1016/j.cmi.2021.02.017
Clinical and Laboratory Standards Institute. M45 Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria 3rd edn (CLSI, 2015).
Burnard, D. et al. Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin. Antimicrob. Agents Chemother. 65, e00685-20 (2021).
pubmed: 33168603
pmcid: 7848980
doi: 10.1128/AAC.00685-20
Tandhavanant, S. et al. Monoclonal antibody-based immunofluorescence microscopy for the rapid identification of Burkholderia pseudomallei in clinical specimens. Am. J. Trop. Med. Hyg. 89, 165–168 (2013).
pubmed: 23716405
pmcid: 3748476
doi: 10.4269/ajtmh.13-0066
Meumann, E. M. et al. Clinical evaluation of a type III secretion system real-time PCR assay for diagnosing melioidosis. J. Clin. Microbiol. 44, 3028–3030 (2006).
pubmed: 16891534
pmcid: 1594648
doi: 10.1128/JCM.00913-06
Amornchai, P. et al. Sensitivity and specificity of DPP® Fever Panel II Asia in the diagnosis of malaria, dengue and melioidosis. J. Med. Microbiol. https://doi.org/10.1099/jmm.0.001584 (2022).
Houghton, R. L. et al. Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis. PLoS Negl. Trop. Dis. 8, e2727 (2014).
pubmed: 24651568
pmcid: 3961207
doi: 10.1371/journal.pntd.0002727
Currie, B. J., Woerle, C., Mayo, M., Meumann, E. M. & Baird, R. W. What is the role of lateral flow immunoassay for the diagnosis of melioidosis? Open Forum Infect. Dis. 9, ofac149 (2022).
pubmed: 35493111
pmcid: 9043003
doi: 10.1093/ofid/ofac149
Chaichana, P. et al. Antibodies in melioidosis: the role of the indirect hemagglutination assay in evaluating patients and exposed populations. Am. J. Trop. Med. Hyg. 99, 1378–1385 (2018). Description of the role of antibodies in diagnosis and immune response to melioidosis.
pubmed: 30298810
pmcid: 6283516
doi: 10.4269/ajtmh.17-0998
Cheng, A. C., O’Brien, M., Freeman, K., Lum, G. & Currie, B. J. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am. J. Trop. Med. Hyg. 74, 330–334 (2006).
pubmed: 16474092
doi: 10.4269/ajtmh.2006.74.330
Davis, J. S. et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun. Dis. Intell. Q. Rep. 27, 526–532 (2003).
pubmed: 15508512
Suttisunhakul, V. et al. Development of rapid enzyme-linked immunosorbent assays for detection of antibodies to Burkholderia pseudomallei. J. Clin. Microbiol. 54, 1259–1268 (2016).
pubmed: 26912754
pmcid: 4844749
doi: 10.1128/JCM.02856-15
Amornchai, P. et al. Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis. PLoS Negl. Trop. Dis. 15, e0009840 (2021).
pubmed: 34727111
pmcid: 8562799
doi: 10.1371/journal.pntd.0009840
Wagner, G. E. et al. Melioidosis DS rapid test: a standardized serological dipstick assay with increased sensitivity and reliability due to multiplex detection. PLoS Negl. Trop. Dis. 14, e0008452 (2020).
pubmed: 32658917
pmcid: 7416965
doi: 10.1371/journal.pntd.0008452
White, N. J. et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 2, 697–701 (1989).
pubmed: 2570956
doi: 10.1016/S0140-6736(89)90768-X
Lipsitz, R. et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg. Infect. Dis. 18, e2 (2012).
pubmed: 23171644
pmcid: 3557896
doi: 10.3201/eid1812.120638
Dance, D. Treatment and prophylaxis of melioidosis. Int. J. Antimicrob. Agents 43, 310–318 (2014).
pubmed: 24613038
pmcid: 4236584
doi: 10.1016/j.ijantimicag.2014.01.005
Pitman, M. C. et al. Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. PLoS Negl. Trop. Dis. 9, e0003586 (2015).
pubmed: 25811783
pmcid: 4374799
doi: 10.1371/journal.pntd.0003586
Sullivan, R. P., Marshall, C. S., Anstey, N. M., Ward, L. & Currie, B. J. 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl. Trop. Dis. 14, e0008659 (2020). Current consensus guidelines for the therapy of melioidosis in the Northern Territory of Australia.
pubmed: 32986699
pmcid: 7544138
doi: 10.1371/journal.pntd.0008659
Suntornsut, P. et al. Effectiveness of a multifaceted prevention programme for melioidosis in diabetics (PREMEL): a stepped-wedge cluster-randomised controlled trial. PLoS Negl. Trop. Dis. 15, e0009060 (2021).
pubmed: 34170931
pmcid: 8266097
doi: 10.1371/journal.pntd.0009060
Majoni, S. W., Hughes, J. T., Heron, B. & Currie, B. J. Trimethoprim+sulfamethoxazole reduces rates of melioidosis in high-risk hemodialysis patients. Kidney Int. Rep. 3, 160–167 (2018).
pubmed: 29340327
doi: 10.1016/j.ekir.2017.09.005
Luangasanatip, N. et al. The global impact and cost-effectiveness of a melioidosis vaccine. BMC Med. 17, 129 (2019).
pubmed: 31272431
pmcid: 6610909
doi: 10.1186/s12916-019-1358-x
International Diabetes Federation. IDF Diabetes Atlas 8th edn (IDF, 2017).
Osterloh, A. Vaccination against bacterial infections: challenges, progress, and new approaches with a focus on intracellular bacteria. Vaccines 10, 751 (2022).
pubmed: 35632507
pmcid: 9144739
doi: 10.3390/vaccines10050751
Morici, L., Torres, A. G. & Titball, R. W. Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clin. Exp. Immunol. 196, 178–188 (2019). Excellent overview of vaccines for melioidosis that are in development.
pubmed: 30963550
pmcid: 6468173
doi: 10.1111/cei.13286
Burtnick, M. N. et al. Development of subunit vaccines that provide high-level protection and sterilizing immunity against acute inhalational melioidosis. Infect. Immun. 86, e00724-17 (2018).
pubmed: 29109172
doi: 10.1128/IAI.00724-17
Burtnick, M. N. et al. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front. Cell Infect. Microbiol. 2, 108 (2012).
pubmed: 22912938
pmcid: 3419357
Scott, A. E. et al. Protection against experimental melioidosis with a synthetic manno-heptopyranose hexasaccharide glycoconjugate. Bioconjug. Chem. 27, 1435–1446 (2016).
pubmed: 27124182
pmcid: 4911622
doi: 10.1021/acs.bioconjchem.5b00525
Scott, A. E. et al. Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis. Infect. Immun. 82, 3206–3213 (2014).
pubmed: 24866807
pmcid: 4136211
doi: 10.1128/IAI.01847-14
Schmidt, L. K. et al. Development of melioidosis subunit vaccines using an enzymatically inactive Burkholderia pseudomallei AhpC. Infect. Immun. 90, e0022222 (2022).
pubmed: 35862715
doi: 10.1128/iai.00222-22
Tomas-Cortazar, J. et al. BpOmpW antigen stimulates the necessary protective T-cell responses against melioidosis. Front. Immunol. 12, 767359 (2021).
pubmed: 34966388
pmcid: 8710444
doi: 10.3389/fimmu.2021.767359
Champion, O. L. et al. Immunisation with proteins expressed during chronic murine melioidosis provides enhanced protection against disease. Vaccine 34, 1665–1671 (2016).
pubmed: 26917010
doi: 10.1016/j.vaccine.2016.02.038
Muruato, L. A. et al. Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against Burkholderia pseudomallei. Clin. Vaccine Immunol. 24, e00206-17 (2017).
pubmed: 28903988
pmcid: 5674190
doi: 10.1128/CVI.00206-17
Tapia, D., Sanchez-Villamil, J. I., Stevenson, H. L. & Torres, A. G. Multicomponent gold-linked glycoconjugate vaccine elicits antigen-specific humoral and mixed T
pubmed: 34182777
doi: 10.1128/mBio.01227-21
Baker, S. M. et al. Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine. NPJ Vaccines 6, 18 (2021).
pubmed: 33514749
pmcid: 7846723
doi: 10.1038/s41541-021-00281-z
Amemiya, K. et al. Deletion of two genes in Burkholderia pseudomallei MSHR668 that target essential amino acids protect acutely infected BALB/c mice and promote long term survival. Vaccines 7, 196 (2019).
pubmed: 31779073
pmcid: 6963190
doi: 10.3390/vaccines7040196
Khakhum, N. et al. Burkholderia pseudomallei ΔtonB Δhcp1 live attenuated vaccine strain elicits full protective immunity against aerosolized melioidosis infection. mSphere 4, e00570-18 (2019).
pubmed: 30602524
pmcid: 6315081
doi: 10.1128/mSphere.00570-18
Scott, A. E. et al. Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule. Clin. Vaccin. Immunol. 20, 1041–1047 (2013).
doi: 10.1128/CVI.00113-13
Wiersinga, W. J., Currie, B. J. & Peacock, S. J. Melioidosis. N. Engl. J. Med. 367, 1035–1044 (2012).
pubmed: 22970946
doi: 10.1056/NEJMra1204699
Tribuddharat, C., Moore, R. A., Baker, P. & Woods, D. E. Burkholderia pseudomallei class a β-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47, 2082–2087 (2003).
pubmed: 12821450
pmcid: 161859
doi: 10.1128/AAC.47.7.2082-2087.2003
Sarovich, D. S. et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS ONE 7, e30789 (2012).
pubmed: 22363490
pmcid: 3283585
doi: 10.1371/journal.pone.0030789
Sarovich, D. S. et al. Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection. Infect. Drug Resist. 5, 129–132 (2012).
pubmed: 22977307
pmcid: 3430440
doi: 10.2147/IDR.S35529
Sam, I. C., See, K. H. & Puthucheary, S. D. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J. Clin. Microbiol. 47, 1556–1558 (2009).
pubmed: 19297597
pmcid: 2681875
doi: 10.1128/JCM.01657-08
Hayden, H. S. et al. Evolution of Burkholderia pseudomallei in recurrent melioidosis. PLoS ONE 7, e36507 (2012).
pubmed: 22615773
pmcid: 3352902
doi: 10.1371/journal.pone.0036507
Bugrysheva, J. V. et al. Antibiotic resistance markers in Burkholderia pseudomallei strain Bp1651 identified by genome sequence analysis. Antimicrob. Agents Chemother. 61, e00010-17 (2017).
pubmed: 28396541
pmcid: 5444168
doi: 10.1128/AAC.00010-17
Price, E. P. et al. Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. mBio 4, e00388-13 (2013).
pubmed: 23860767
pmcid: 3735121
doi: 10.1128/mBio.00388-13
Chantratita, N. et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc. Natl Acad. Sci. USA 108, 17165–17170 (2011).
pubmed: 21969582
pmcid: 3193241
doi: 10.1073/pnas.1111020108
Podnecky, N. L. et al. Mechanisms of resistance to folate pathway inhibitors in Burkholderia pseudomallei: deviation from the norm. mBio 8, e01357-17 (2017).
pubmed: 28874476
pmcid: 5587915
doi: 10.1128/mBio.01357-17
Sarovich, D. S. et al. Raising the stakes: loss of efflux pump regulation decreases meropenem susceptibility in Burkholderia pseudomallei. Clin. Infect. Dis. 67, 243–250 (2018).
pubmed: 29394337
doi: 10.1093/cid/ciy069
Madden, D. E. et al. Taking the next-gen step: comprehensive antimicrobial resistance detection from Burkholderia pseudomallei. EBioMedicine 63, 103152 (2021).
pubmed: 33285499
doi: 10.1016/j.ebiom.2020.103152
Webb, J. R., Price, E. P., Currie, B. J. & Sarovich, D. S. Loss of methyltransferase function and increased efflux activity leads to doxycycline resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 61, e00268-17 (2017).
pubmed: 28348161
pmcid: 5444123
doi: 10.1128/AAC.00268-17
Hall, C. M. et al. Exploring cefiderocol resistance mechanisms in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 67, e0017123 (2023).
pubmed: 37133377
doi: 10.1128/aac.00171-23
Chaichana, P. et al. A nonsense mutation in TLR5 is associated with survival and reduced IL-10 and TNF-α levels in human melioidosis. PLoS Negl. Trop. Dis. 11, e0005587 (2017).
pubmed: 28475641
pmcid: 5435357
doi: 10.1371/journal.pntd.0005587
Chanchamroen, S., Kewcharoenwong, C., Susaengrat, W., Ato, M. & Lertmemongkolchai, G. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect. Immun. 77, 456–463 (2009).
pubmed: 18955471
doi: 10.1128/IAI.00503-08
Jones, S. M., Ellis, J. F., Russell, P., Griffin, K. F. & Oyston, P. C. F. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 51, 1055–1062 (2002).
pubmed: 12466403
doi: 10.1099/0022-1317-51-12-1055
AuCoin, D. P. et al. Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. PLoS ONE 7, e35386 (2012).
pubmed: 22530013
pmcid: 3328442
doi: 10.1371/journal.pone.0035386
Charuchaimontri, C. et al. Antilipopolysaccharide II: an antibody protective against fatal melioidosis. Clin. Infect. Dis. 29, 813–818 (1999).
pubmed: 10589895
doi: 10.1086/520441
Ho, M. et al. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 65, 3648–3653 (1997).
pubmed: 9284132
pmcid: 175519
doi: 10.1128/iai.65.9.3648-3653.1997
Chaichana, P. et al. Serum from melioidosis survivors diminished intracellular Burkholderia pseudomallei growth in macrophages: a brief research report. Front. Cell Infect. Microbiol. 10, 442 (2020).
pubmed: 32984070
pmcid: 7479196
doi: 10.3389/fcimb.2020.00442
Pumpuang, A., Paksanont, S., Burtnick, M. N., Brett, P. J. & Chantratita, N. Functional activities of O-polysaccharide and hemolysin coregulated protein 1 specific antibodies isolated from melioidosis patients. Infect. Immun. 90, e0021422 (2022).
pubmed: 36226942
doi: 10.1128/iai.00214-22
Santanirand, P., Harley, V. S., Dance, D. A., Drasar, B. S. & Bancroft, G. J. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 67, 3593–3600 (1999).
pubmed: 10377144
pmcid: 116549
doi: 10.1128/IAI.67.7.3593-3600.1999
Dharakul, T. et al. HLA-DR and -DQ associations with melioidosis. Hum. Immunol. 59, 580–586 (1998).
pubmed: 9757914
doi: 10.1016/S0198-8859(98)00052-4
Tippayawat, P. et al. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl. Trop. Dis. 3, e407 (2009).
pubmed: 19352426
pmcid: 2660609
doi: 10.1371/journal.pntd.0000407
Chierakul, W. et al. Short report: disease severity and outcome of melioidosis in HIV coinfected individuals. Am. J. Trop. Med. Hyg. 73, 1165–1166 (2005).
pubmed: 16354832
doi: 10.4269/ajtmh.2005.73.1165